{"id":"batch-3-of-ad5-ncov","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or swelling"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL2398389","moleculeType":"Small molecule","molecularWeight":"410.55"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine uses a replication-deficient adenovirus serotype 5 as a viral vector to introduce genetic material encoding the SARS-CoV-2 spike protein into host cells. This triggers both cellular and humoral immune responses, including T-cell and antibody production against the spike protein, providing protection against COVID-19 infection and severe disease.","oneSentence":"Ad5-nCoV is a recombinant adenovirus type 5 vector vaccine that delivers the SARS-CoV-2 spike protein gene to stimulate immune responses against COVID-19.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:40:26.467Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention"}]},"trialDetails":[{"nctId":"NCT05313646","phase":"PHASE4","title":"Clinical Evaluation for Batch Consistency of Ad5-nCoV in Chinese Healthy Adults","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2021-03-08","conditions":"COVID-19","enrollment":1050}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Convidecia"],"phase":"marketed","status":"active","brandName":"batch 3 of Ad5-nCoV","genericName":"batch 3 of Ad5-nCoV","companyName":"Jiangsu Province Centers for Disease Control and Prevention","companyId":"jiangsu-province-centers-for-disease-control-and-prevention","modality":"Biologic","firstApprovalDate":"","aiSummary":"Ad5-nCoV is a recombinant adenovirus type 5 vector vaccine that delivers the SARS-CoV-2 spike protein gene to stimulate immune responses against COVID-19. Used for COVID-19 prevention.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}